Alnylam Partners with AI Pioneer Inceptive in $2B Collaboration to Accelerate RNAi Drug Discovery
核心洞察
Alnylam Pharmaceuticals (搜索) and Inceptive Nucleics (搜索) announced a strategic three-year collaboration valued at up to $2 billion, with $30 million upfront, to accelerate RNAi therapeutic discovery using AI foundation models.
The partnership combines Alnylam's 20+ years of proprietary siRNA data and six approved drugs with Inceptive's generative AI models led by Jakob Uszkoreit, co-inventor of the Transformer architecture.
Inceptive's foundation models demonstrated exceptional performance in characterizing siRNA molecules within weeks during joint exploratory work, potentially revolutionizing drug design beyond traditional trial-and-error approaches.
Alnylam Pharmaceuticals (搜索) and Inceptive Nucleics (搜索) announced a strategic collaboration valued at up to $2 billion to integrate artificial intelligence foundation models with RNA interference (RNAi) therapeutics discovery. The three-year partnership includes $30 million in upfront consideration through cash and equity purchase, with additional milestone-based payments tied to preclinical, regulatory, and commercial achievements.
AI Meets Established RNAi Platform
The collaboration pairs Alnylam's proven RNAi platform, which has produced six approved drugs backed by over 20 years of proprietary siRNA data, with Inceptive's generative AI models. Inceptive's foundation model learns underlying biological patterns and can adapt to diverse therapeutic modalities without retraining, representing a departure from traditional trial-and-error drug discovery approaches.
"We're thrilled to partner with Inceptive to push the boundaries of what is possible in the discovery of RNAi medicines," said Yvonne Greenstreet, M.D., Chief Executive Officer of Alnylam. "Together, we have an extraordinary opportunity to accelerate the creation of transformative medicines with a speed, ingenuity, and sophistication that simply has not been possible before."
Proven AI Leadership in Drug Design
Inceptive is led by Jakob Uszkoreit, who co-invented the Transformer architecture underlying ChatGPT during his tenure at Google Brain (搜索). After over a dozen years at Google, Uszkoreit founded Inceptive Nucleics (搜索) in 2021 to build "AI foundation models of life" that can generalize across multiple biological tasks.
"Most drug design still works through a process of trial and error, testing thousands of molecules and hoping something sticks," said Uszkoreit. "Inceptive was built on a different premise: that life follows rules of such complexity that only AI can learn them."
Early Results Demonstrate Promise
In joint exploratory work, Inceptive's foundation model achieved exceptional performance within weeks, uncovering meaningful biological insights from relatively small datasets to characterize siRNA molecules, the active ingredient in RNAi therapeutics (搜索). The model's ability to rapidly generate insights from limited data represents a significant advancement over conventional approaches.
Strategic Focus on siRNA Enhancement
The collaboration will advance siRNA design by modeling target mRNAs and jointly exploring sequence space and novel chemical modifications to enhance potency and efficacy. The AI models will predict top-performing therapeutic candidates in preclinical models for further development by Alnylam, helping prioritize the most promising molecules and improve experimental productivity.
The partnership provides Alnylam access to Inceptive's AI expertise and talent, including pioneers of scalable, AI-enabled wet-lab training data generation methods. This integration supports Alnylam's ambitious pipeline expansion goals as part of its Alnylam 2030 strategy to accelerate innovation and scale impact.
Financial Context and Market Position
The $2 billion collaboration value represents a significant investment relative to Alnylam's 2025 total revenues of $3.7 billion. Inceptive, founded in 2021, is backed by prominent investors including a16z (搜索), NVIDIA (搜索), S32, and Obvious, with headquarters in Palo Alto and offices in Berlin and Zurich.
Alnylam has established itself as the leading RNAi therapeutics (搜索) company with medicines available in more than 70 countries and a rapidly expanding pipeline. The company has advanced Nobel Prize-winning RNAi science for over two decades, delivering critical breakthroughs across multiple therapeutic areas.